Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04499534 · ClinicalTrials.gov registry record
BRCA1/2 Flu Vaccine
A clinical trial of BRCA1 Mutation and BRCA2 Mutation, sponsored by Abramson Cancer Center at Penn Medicine.
- Active
- Registry status
- 50
- Enrollment target
- 1
- Study location
NCT04499534: Active study of BRCA1 Mutation and BRCA2 Mutation, sponsored by Abramson Cancer Center at Penn Medicine.
NCT04499534 is a study of BRCA1 Mutation and BRCA2 Mutation that is active but no longer recruiting, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 50 participants, below the 574-participant average among 15 other BRCA1 Mutation trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04499534, a study of BRCA1 Mutation and BRCA2 Mutation, is active but no longer recruiting, sponsored by Abramson Cancer Center at Penn Medicine.
- ACTIVE NOT RECRUITING
- Registry status
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
To evaluate immune function in BRCA1/2 mutation carriers without cancer, specifically to determine whether immune function in healthy individuals with germline loss of function BRCA1/2 mutations, impacts overall immune health and fitness.
Primary Outcome
Analysis of the primary objective will depend on determination of the strain-specific neutralizing antibody titer change from day 0 to the last study visit, performed as the standard assay as described by the World Health Organization (WHO).
Conditions Studied
Interventions
- BIOLOGICAL Seasonal influenza vaccine
Study Locations (1)
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2019-10-28 |
| Est. Completion | 2026-06 |
What the registry record for NCT04499534 still lists
NCT04499534 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 574-participant average among 15 other BRCA1 Mutation trials with a reported enrollment target (91% lower).
The record links to 2 conditions, with BRCA1 Mutation appearing as the primary indexed condition, and to 1 intervention - of which Seasonal influenza vaccine is the first listed.
NCT04499534 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04499534 about?
NCT04499534 is a clinical study titled "BRCA1/2 Flu Vaccine". To evaluate immune function in BRCA1/2 mutation carriers without cancer, specifically to determine whether immune function in healthy individuals with germline loss of function BRCA1/2 mutations, impacts overall immune health and fitness.
What is the current status of trial NCT04499534?
This trial is currently active not recruiting. The enrollment target is 50 participants. The study started on 2019-10-28. Estimated completion is 2026-06.
What conditions does trial NCT04499534 study?
This clinical trial studies the following conditions: BRCA1 Mutation, BRCA2 Mutation.
What interventions are being tested in trial NCT04499534?
The interventions under investigation include: Seasonal influenza vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT04499534?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04499534 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for BRCA1 Mutation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04499534's enrollment target sits among peer trials
50 9th of 15 higher than 6 of 15 other BRCA1 Mutation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other BRCA1 Mutation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
An Intervention to Increase Genetic Testing in Families Who May Share a Gene Mutation Related to Cancer Risk and An Intervention to Help Patients and Their Primary Care Providers Stay Up-to-date About Uncertain Genetic Test Results
RECRUITING · NA
-
SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
RECRUITING · Phase 1
-
Combination Therapy in Cancers With Mutations in DNA Repair Genes
RECRUITING · Phase 1
-
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors
RECRUITING · Phase 1
-
Hormone Replacement Therapy After Risk Reducing Salpingo-oophorectomy
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI